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Dynamic interaction of SARAF with 
STIM1 and Orai1 to modulate store-
operated calcium entry
Letizia Albarran1, Jose J. Lopez1, Nidhal Ben Amor1, Francisco E. Martin-Cano1, 
Alejandro Berna-Erro1, Tarik Smani2, Gines M. Salido1 & Juan A. Rosado1
Ca2+ influx by store-operated Ca2+ channels is a major mechanism for intracellular Ca2+ homeostasis 
and cellular function. Here we present evidence for the dynamic interaction between the SOCE-
associated regulatory factor (SARAF), STIM1 and Orai1. SARAF overexpression attenuated SOCE and 
the STIM1-Orai1 interaction in cells endogenously expressing STIM1 and Orai1 while RNAi-mediated 
SARAF silencing induced opposite effects. SARAF impaired the association between Orai1 and the 
Orai1-activating small fragment of STIM1 co-expressed in the STIM1-deficient NG115-401L cells. 
Cell treatment with thapsigargin or physiological agonists results in direct association of SARAF with 
Orai1. STIM1-independent interaction of SARAF with Orai1 leads to activation of this channel. In cells 
endogenously expressing STIM1 and Orai1, Ca2+ store depletion leads to dissociation of SARAF with 
STIM1 approximately 30s after treatment with thapsigargin, which paralleled the increase in SARAF-
Orai1 interaction, followed by reinteraction with STIM1 and dissociation from Orai1. Co-expression 
of SARAF and either Orai1 or various N-terminal deletion Orai1 mutants did not alter SARAF-Orai1 
interaction; however, expression of C-terminal deletion Orai1 mutants or blockade of the C-terminus 
of Orai1 impair the interaction with SARAF. These observations suggest that SARAF exerts an initial 
positive role in the activation of SOCE followed by the facilitation of SCDI of Orai1.
Store operated Ca2+ entry (SOCE) is a major pathway of calcium influx in non-excitable cells, and is essential for 
the activation of many cellular processes. This mechanism is initiated by the depletion of the intracellular Ca2+ 
stores, mainly the endoplasmic reticulum (ER). The two major components of SOCE are STIM11,2, the Ca2+ sen-
sor of the ER that communicates the signal of store depletion to the plasma membrane resident Ca2+ channel, and 
the channel pore-forming Orai13–5.
Orai1 is a highly Ca2+-selective, inward-rectifying, channel that has been reported to be regulated by Ca2+ 
in two possible ways named fast Ca2+-dependent inactivation (FCDI), which occurs within milliseconds6,7, and 
slow Ca2+-dependent inactivation (SCDI) that inactivates Orai1 over 2–3 min to prevent Ca2+ overload8,9. The 
later mechanism is activated by Ca2+ entering through Orai1 channels, and constitutes a slow negative feedback 
process. SCDI has been reported to include both store refilling-dependent and independent components in Jurkat 
T cells8; although it has been found to be entirely independent on store refilling in rat basophilic leukemia cells9.
STIM1 N-terminus exhibits an EF-hand motif, which, upon Ca2+ dissociation, leads to oligomerization and 
clustering of STIM1 into puncta located at the ER–plasma membrane junctions10. This transition is accompanied 
by a conformational reorganization of its cytosolic region from a closed to an extended state leading to the expo-
sition of the SOAR domain (amino acids 344–44211; also known as OASF (233–450/474)12, CAD (342–448)13 or 
Ccb9 (339–444)14), which results in full activation of Orai115. The crystal structure of SOAR has revealed that this 
domain exists as a V-shaped dimer16. In the resting state, STIM1 may exist mostly as dimers with the SOAR dimer 
likely occluded. In the inactive state, the Ca2+ bound intraluminal region remains monomeric10 but, upon Ca2+ 
store depletion, the N-terminal region of STIM1 releases Ca2+ and oligomerizes resulting in the conformational 
change that releases the SOAR domain16.
Recent studies have identified a C-terminal inhibitory domain (CTID; amino acids 448–530) downstream 
of the SOAR domain, whose deletion leads to spontaneous clustering of STIM1 and activation of Orai1 in the 
absence of Ca2+ store depletion17. CTID has been reported to mediate the interaction of STIM1 with a new 
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Figure 1. SARAF regulates TG-induced SOCE and STIM1-Orai1 interaction. (a,b) MEG-01 cells 
overexpressing SARAF and mock-treated cells (a) or MEG-01 cells transfected with si SARAF or scramble 
plasmid (b) were perfused with a Ca2+-free medium (100 μM EGTA added) and then stimulated with TG 
(1 μM) followed by reintroduction of external Ca2+ (final concentration 300 μM) to initiate Ca2+ entry. Data 
are original traces representative of 42-58 experiments. Values are expressed as described in methods. The bar 
graph represents TG-induced Ca2+ entry as mean ± SEM and data are presented as percentage of control.  
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regulatory protein named SARAF17. SARAF is a 339-amino acid long protein with a putative single transmem-
brane domain and C-terminal serine/proline and arginine rich regions. SARAF is located in the membrane of 
the endoplasmic reticulum and interacts with the CTID region of STIM1 to mediate SCDI of Orai1 channels18. 
CTID has been described to have two functional lobes, STIM1(448–490) and STIM1(490–530), which cooperate 
to modulate the access of SARAF to the SOAR region, so that in the resting state, when the intracellular stores 
are filled with Ca2+, the CTID lobes facilitate access of SARAF to SOAR to keep SOAR in an inactive state, while 
store depletion results in an initial dissociation of SARAF, to allow activation of STIM1 and SOCE, followed by a 
reinteraction of SARAF with SOAR, facilitated by the STIM1(490–530) lobe, a process that has been associated 
with the SCDI of Orai117.
In the present study we have investigated the interaction of SARAF with STIM1 and Orai1 during the acti-
vation of SOCE. Our results indicate that SARAF is a modulator of the interaction between STIM1 and Orai1 
channels that, during the initial steps of the activation of SOCE, transiently dissociates from STIM1 to associate 
with the C-terminus of Orai1 to activate Ca2+ entry, and then reinteracts with STIM1 to mediate SCDI. These 
findings shed new light on the regulatory mechanism of SOCE.
Results
SARAF regulates store-operated Ca2+ entry and STIM1-Orai1 interaction. As depicted in Fig. 1a, 
treatment of MEG-01 cells with thapsigargin (TG) in a Ca2+-free medium resulted in a transient rise in cytosolic 
Ca2+ concentration ([Ca2+]c) due to passive Ca2+ release from the intracellular stores. The subsequent SOCE, 
upon readdition of Ca2+ to the medium, was significantly inhibited by 45% in cells overexpressing SARAF 
(p < 0.001). As expected, SOCE was significantly enhanced by 20% in cells where endogenous SARAF levels were 
reduced by siRNA (Fig. 1b; p < 0.05).
To further explore the mechanism underlying the regulation of SOCE by SARAF we modified the expression 
of SARAF in MEG-01 cells endogenously expressing STIM1 and Orai119, as well as SARAF (Fig. 1c), and inves-
tigated the role of SARAF in the interaction between STIM1 and Orai1. The experiments were performed in 
resting cells and upon stimulation with TG by looking for co-immunoprecipitation in whole cell lysates from cells 
overexpressing SARAF and SARAF-silenced cells. As shown in Fig. 1d, a detectable interaction between STIM1 
and Orai1 was noticeable in resting cells, as previously described19. This interaction was significantly enhanced 
to 253 ± 30% of control after Ca2+ store depletion. Overexpression of SARAF abolished TG-evoked interaction 
between STIM1 and Orai1 without having any significant effect on the resting interaction between both proteins. 
Consistent with this, SARAF silencing significantly enhanced the STIM1-Orai1 interaction induced by TG to 
325 ± 21% of control (p < 0.05) and had a negligible effect on this interaction in resting cells. Analysis of the 
specificity of the anti-Orai1 and anti-STIM1 antibodies is depicted in the supplementary Fig. 1.
In an attempt to ascertain the role of SARAF in the STIM1-Orai1 association in Ca2+ store-depleted cells, we 
analyzed the interaction between Orai1 and the Orai1-activating small fragment (OASF; amino acids 233–474) 
of STIM1 in NG115-401L cells, which express a negligible amount of endogenous STIM120,21. Cells were trans-
fected with expression plasmids for pEYFP-Orai1 and pEYFP-OASF in combination with siSARAF or expression 
plasmid for SARAF. As shown in Fig. 2, co-expression of Orai1 and OASF resulted in a robust activation of Ca2+ 
entry independently of Ca2+ store depletion as compared to mock-treated cells, which did not display constitutive 
Ca2+ entry. Ca2+ entry induced by co-expression of Orai1 and OASF was impaired by overexpression of SARAF 
and enhanced by SARAF silencing (Fig. 2), thus suggesting that SARAF directly interferes with the interaction 
between the OASF region of STIM1 and Orai1.
SARAF interacts with STIM1 and Orai1. It has been suggested that SARAF is associated with STIM1 
in resting cells and upon store depletion undergoes dissociation of STIM1 followed by reinteraction to activate 
SCDI17; however, the functional role of SARAF when it is dissociated from STIM1 remains unknown. We have 
now further explored the temporal relationship of the association of SARAF with STIM1 and Orai1 in MEG-01 
cells. We have explored the interaction of SARAF with STIM1 or Orai1 by in situ proximity ligation assay (PLA). 
Resting MEG-01 cells or cells stimulated with TG (1 μM) for 30 or 120 s were subjected to PLA. As shown in 
Fig. 3 under resting conditions SARAF-Orai1 and SARAF-STIM1 interactions were detected in most cells ana-
lyzed. Treatment of MEG01 cells with TG (1 μM) for 30 s enhanced the interaction SARAF-Orai1 as detected 
by the increased number of red dots, as compared to control. However, the number of associations between 
SARAF and STIM1 per cell was significantly reduced (and we were unable to detected them in a number of cells) 
(c) Cells overexpressing SARAF, treated with siSARAF and mock-treated cells were lysed and subjected to 
Western blotting with anti-SARAF antibody, followed by reprobing with anti-actin antibody for protein loading 
control. (d) MEG-01 cells overexpressing SARAF or transfected with si SARAF and their respective controls 
were stimulated with TG (1 μM) in a Ca2+-free medium (100 μM EGTA added) and three min later lysed. Whole 
cell lysates were immunoprecipitated (IP) with anti-STIM1 antibody and immunoprecipitates were subjected 
to 10% SDS-PAGE and subsequent Western blotting with a specific anti-Orai1 (aa 288–301 (Sigma)) antibody. 
Membranes were reprobed with the antibody used for immunoprecipitation for protein loading control. The 
panels show results from one experiment representative of 6–7 others. Molecular masses indicated on the right 
were determined using molecular-mass markers run in the same gel. HC, heavy chain of the antibody used 
for immunoprecipitation. The bar graph represents the quantification of STIM1-Orai1 association in resting 
and TG-treated cells. Results are recorded as arbitrary optical density units, expressed as mean ± S.E.M. and 
presented as percentage of control. * and *** represent p < 0.05 and p < 0.001, as compared to their respective 
controls.
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upon stimulation for 30 s with TG. After 120 s of treatment with TG the number of red dots/cell representative 
of SARAF-Orai1 as well as SARAF-STIM1 interaction returned to levels similar to those observed in resting 
cells. The quantification of the PLA signal for the interaction between SARAF and STIM1 or SARAF and Orai1 
revealed that treatment with TG enhanced the interaction between SARAF and Orai1 reaching a maximum of 
215 ± 21% of control (resting cells) after 30 s of stimulation and then returned to approximately the resting level 
after 120 s of treatment (Fig. 3; p < 0.001); Furthermore, TG significantly reduced the association between SARAF 
and STIM1 reaching a minimum of 48 ± 7% of control after 30 s of stimulated and then increased, reaching the 
resting level at 120 s of treatment (Fig. 3; p < 0.001). These findings support the dynamic interaction of SARAF 
with STIM1 and Orai1 upon treatment with TG.
We further explored the interaction between SARAF and both STIM1 and Orai1 by co-immunoprecipitation. 
As shown in Fig. 4a, a detectable interaction between SARAF and both STIM1 and Orai1 was appreciable in 
resting cells. Treatment of MEG-01 cells with TG evoked a time-dependent effect on the association of SARAF 
Figure 2. SARAF impairs OASF-dependent Orai1 function. NG115-401L cells were transfected with pEYPF-
Orai1 and pEYPF-OASF in the absence of presence of SARAF or siSARAF or were mock treated, as indicated. 
After 48h cells were perfused with a Ca2+-free medium (100 μM EGTA added) followed by reintroduction 
of external Ca2+ (final concentration 1 mM) to initiate constitutive Ca2+ entry. Data are original traces 
representative of 42–58 experiments. Values are expressed as described in methods.
Figure 3. Dynamic interaction of SARAF with Orai1 and STIM1. MEG-01 cells were suspended in HBS 
containing 300 μM CaCl2 and were left untreated or stimulated with TG (1 μM) for 30 or 120 s. The cells were 
then fixed with 4% ice-cold paraformaldehyde and blocked using blocking solution from the Duolink In Situ 
Red kit® from Sigma. Samples were incubated with primary antibodies: rabbit anti-SARAF and mouse anti-
STIM1 or mouse anti-Orai1 (SAB4200273, Sigma) antibodies. A Duolink assay was subsequently performed 
according to the manufacturer’s instructions as described in Material and Methods. After performing the PLA 
procedure, images were taken with an Eclipse TE300 fluorescence microscope. Red spots represent individual 
dimers. The positive control is shown in the lower right corner. The bars indicate 10 μm. The bar graphs indicate 
association between SARAF and STIM1 or Orai1 expressed as the mean ± S.E.M. of 100–200 cells. The 
quantification of PLA signals was performed using ImageJ software. ***p < 0.001.
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with STIM1 and Orai1. TG induced an initial significant decrease in SARAF-STIM1 interaction that reached a 
minimum of 35% of the resting level 30s after stimulation (p < 0.001). SARAF-STIM1 interaction then increased, 
exceeding basal levels approximately 120s after stimulation. In parallel with these findings, treatment with TG 
significantly increased the association between SARAF and Orai1 reaching a maximum of 190% of the resting 
level 30 s after its addition (p < 0.001) and then returned to the basal level at 120 s after stimulation (Fig. 4a).
In order to explore whether the interaction SARAF-Orai1 requires STIM1 we repeated the study in NG115-
401L cells lacking STIM1. As reported in Fig. 4b, our results indicate that, in the absence of STIM1, TG evokes 
association between SARAF and Orai1, which reached a maximum 30 s after cell stimulation (p < 0.001). These 
findings indicate that STIM1 is not responsible for the dissociation of the interaction between SARAF and Orai1.
SARAF modulates Ca2+ entry through Orai1 independently of STIM1. To understand the func-
tional significance of the interaction of SARAF with Orai1 independently of STIM1 we determined Ca2+ entry 
in NG115-401L cells transfected with expression plasmid for Orai1 in combination with SARAF overexpression 
or siSARAF. Since NG115-401L cells release Ca2+ in response to TG but do not display SOCE21, we used ATP, 
as a physiological agonist, to stimulate Ca2+ entry. As depicted in Fig. 5a, stimulation of NG115-401L cells with 
100 μM ATP in a Ca2+-free medium resulted in a transient rise in [Ca2+]c due to Ca2+ release from the intracel-
lular stores. Overexpression of Orai1 alone or in combination with either SARAF silencing or overexpression 
did not significantly modify the ability of ATP to release Ca2+ from the stores. If we consider the entry of Ca2+ 
stimulated by ATP, Orai1 overexpression resulted in a significant increase in Ca2+ influx to 187 ± 12% of control 
(Fig. 5b; p < 0.05), thus suggesting functional expression of Orai1. SARAF silencing did not significantly altered 
ATP-induced Ca2+ entry per se but abolished the additional Ca2+ influx observed in cells overexpressing Orai1 
(Fig. 5b,d; p < 0.05). By contrast, SARAF overexpression significantly increased ATP-stimulated Ca2+ influx in 
the wild type as well as in the Orai1-overexpressing NG115-401L cells (Fig. 5b,d; p < 0.05). Figure. 5c shows the 
amount of Ca2+ accumulated in the intracellular Ca2+ stores, estimated by organelle content release using iono-
mycin (2 μM). As depicted in Fig. 5c, Orai1 expressing did not significantly alter the ability of NG115-401L cells 
to accumulate Ca2+ into the stores but SARAF silencing significantly enhanced the amount of Ca2+ released using 
Figure 4. Time-course of TG-induced SARAF-STIM1 and SARAF-Orai1 co-immunoprecipitation. MEG-
01 cells (a) and NG115-401L cells (b) were stimulated with TG (1 μM) in the presence of 300 μM extracellular 
Ca2+. Samples were removed 30s before the addition of TG and 30, 60 and 120 s after the treatment with 
TG. Whole cell lysates were immunoprecipitated (IP) with the indicated antibody and immunoprecipitates 
were subjected to 10% SDS-PAGE and subsequent Western blotting with specific anti-Orai1 (aa 288–301 
(Sigma)), anti-SARAF and anti-STIM1 antibodies. Membranes were reprobed with the antibody used for 
immunoprecipitation for protein loading control. The panels show results from one experiment representative 
of 5 others. Molecular masses indicated on the right were determined using molecular-mass markers run in the 
same gel. HC, heavy chain of the antibody used for immunoprecipitation. Data represent the quantification of 
SARAF-Orai1 and SARAF-STIM1 association in resting and TG-treated cells. Results are recorded as arbitrary 
optical density units, expressed as mean ± S.E.M. and presented as percentage of control (resting cells). * and 
*** represent p < 0.05 and p < 0.001, as compared to controls.
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Figure 5. SARAF regulates Orai1 channel function. (a–c) NG115-401L cells were transfected with Orai1, 
SARAF, siSARAF or empty vector as control (Mock). Cells were perfused with a Ca2+-free medium (100 μM 
EGTA added) (a,c) or a medium containing 1 mM Ca2+ (b) and then stimulated with ATP (100 μM; (a,b)) 
or ionomycin (2 μM, (c)). Data are original traces representative of 22–171 experiments. (d) The bar graph 
represents ATP-evoked Ca2+ entry estimated as the integral of the rise in [Ca2+]c above basal for 1½ min after 
the addition of ATP in the presence of external Ca2+, corrected by subtraction of the integral over the same 
period for stimulation with ATP in the absence of external Ca2+. Data are expressed as mean ± SEM and 
presented as percentage of control (mock-treated cells). * and φ represent p < 0.05 as compared to ATP-induced 
Ca2+ entry in mock-treated controls or cells overexpressing Orai1, respectively. (e) Immunoblot analysis 
of SARAF and Orai1 expressed in NG115-401L cells before or after treatment with siSARAF or expression 
plasmids for SARAF and Orai1 using anti-SARAF antibody and anti-Orai1 antibody (aa 288–301 (Sigma)). 
Membranes were reprobed with anti-β -actin antibody for protein loading control. The panel shows results from 
one experiment representative of 3 others. Molecular masses indicated on the right were determined using 
molecular-mass markers run in the same gel.
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ionomycin by 20% (p < 0.05) as previously described in HeLa and Jurkat cells18. Figure 5e, shows the expression 
of SARAF and Orai1 proteins in cells treated as mentioned above. These findings indicate that SARAF plays a 
positive regulatory role on Orai1 channel function, and, together with the data presented in Figs 2–4, provide 
evidence for the first time of a direct and functional interaction of SARAF with Orai1.
Blockade of the C-terminal region of Orai1 displays a significant reduction in SARAF binding. 
Finally, we have investigated the location of the possible SARAF binding site of Orai1 in NG115-401L cells 
overexpressing pEYFP-Orai1 (full-length), the N-terminal deletion mutants (pEYFP-Orai1 ΔN1–38, ΔN1–72 
and ΔN1–89) or the C-terminal deletion mutant (Orai1-ΔCtermin, amino acids 1–260) together with SARAF. 
As shown in Fig. 6a, our results indicate that co-expression of pEYFP-Orai1 and SARAF show detectable 
co-immunoprecipitation between both proteins, which was not altered in cells co-transfected with SARAF and the 
N-terminal truncations of Orai1 described above, which strongly indicates that the cytosolic N-terminal region 
of Orai1 is not required for SARAF interaction. By contrast, we were unable to detect co-immunoprecipitation 
between SARAF and the Orai1-ΔCtermin (Fig. 6b,c), thus suggesting that SARAF interacts with the C-terminus 
of Orai1.
To further assess the relevance of the C-terminal region of Orai1 in the interaction with SARAF we used a 
manoeuvre based on the blockade of this region by introduction of an antibody that specifically recognizes the 
sequence 288–301 of Orai1 (anti-Orai1CT, Sigma) as compared to the introduction of an antibody that recog-
nizes 18 amino acids located in the N-terminal region (anti-Orai1NT, Prosci). The presence of these antibodies 
inside the cells was investigated by immunoprecipitation without adding any additional anti-Orai1 antibody and 
subsequent Western blotting with the anti-Orai1 antibody (288–301, Sigma)22. As shown in the supplemental 
Fig. 2a, first lane, Orai1 was clearly detected in cells that had been previously transfected with anti-Orai1CT or 
anti-Orai1NT antibodies. A faint band was detected when the Western blot was performed in the absence of 
primary antibody (primary-free control; supplemental Fig. 2a second lane), which reveals that the band detected 
by Western blotting using anti-Orai1 antibody was specifically Orai1. Cells transfection with anti-Orai1CT sig-
nificantly attenuated the interaction of Orai1 with SARAF as compared to cells transfected with anti-Orai1NT or 
non-specific rabbit IgG (supplemental Fig. 2b,c). The lack of effect of transfection with anti-Orai1NT confirms the 
Figure 6. Analysis of the Orai1 site that interacts with SARAF. NG115-401L cells were transfected with 
SARAF alone or in combination with either pEYFP-full-length Orai1 (FL-Orai1), the N-terminal deletion 
mutants (pEYFP-Orai1 ΔN1–38 (Orai1 ΔN1–38), ΔN1–72 (Orai1 ΔN1–72) and ΔN1–89 (Orai1 ΔN1–89) (a), pEYFP-
Orai1 C-terminal deletion mutant (Orai1-ΔCtermin, amino acids 1–260 (b,c) or empty vector (Mock), as 
indicated. After 48 h cells were lysed and the whole cell lysates were immunoprecipitated (IP) with anti-SARAF 
antibody (a,b) or anti-YFP antibody (c). Immunoprecipitates were subjected to 10% SDS-PAGE and subsequent 
Western blotting with a specific anti-Orai1 (amino acids 288–301, Sigma) antibody (a), anti-Orai1 (ab177021, 
Abcam) antibody (b) or anti-SARAF antibody (c). Membranes were reprobed with the antibody used for 
immunoprecipitation for protein loading control (middle panels). (a,b) Alternatively, the cell lysates were 
subjected to 10% SDS-PAGE and subsequent Western blotting with anti-Orai1 antibody (specific for amino 
acids 288–301; panel a, bottom) or with anti-Orai1 (ab177021, Abcam; panel b, bottom). HC, heavy chain of 
the antibody used for immunoprecipitation. The panels show results from one experiment representative of 
3 others. Molecular masses indicated on the right were determined using molecular-mass markers run in the 
same gel.
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results obtained using different N-terminal deletion mutants. These findings indicate that SARAF interacts with 
a site located in the C-terminus of Orai1.
Discussion
The present study provides relevant information concerning the mechanism of SOCE regulation by SARAF. We 
have found for the first time that SARAF associates with Orai1 and enhances Orai1 function in STIM1-deficient 
cells. SARAF interacts with the C-terminal region of Orai1 since Orai1 constructs lacking the C-terminus are 
unable to associate with SARAF and blockade of this region also impairs its ability to interact with SARAF. Our 
results suggest that SARAF dissociates from STIM1 upon Ca2+ store discharge probably to interact with Orai1 
and cooperate with STIM1 in the activation of Orai1 and, then SARAF rapidly re-associates with STIM1 (and 
dissociates from Orai1) to participate in the inactivation of SOCE. Our results indicate that SARAF interacts and 
activates Orai1 channels in a scenario that allows direct association of both proteins independently of STIM1, 
which has been reported to be negative regulated by SARAF17,18.
Current evidence indicates that the Orai1 forming channels (i.e. CRAC, arachidonic acid-regulated Ca2+ 
and leukotriene C4-regulated Ca2+ channels23–25) are mostly regulated by STIM1. Similarly, there is a body of 
evidence for a role of STIM1 in the regulation of TRP channels as components of store-operated Ca2+ (SOC) 
channels, also involving Orai1 subunits22,26–30, Interestingly, Jha and coworkers have reported that, while in 
the resting state SARAF binds to SOAR in STIM1 (a process regulated by the CTID lobes), activation of Orai1 
after Ca2+ store depletion requires dissociation of SARAF to allow SOAR to interact with and activate Orai1 
channels. Subsequently, SARAF associates again with STIM1 to mediate SCDI. These findings are based on the 
observation that Orai1 current activated by the constitutively active STIM1(4E/4A) and STIM1(D76A) mutants 
was unaffected by SARAF, as well as on the role of different STIM1 mutants on SCDI of Orai1 currents17. In 
agreement with this study, we have found that SARAF, which co-immunoprecipitates with STIM1 under resting 
conditions, dissociates from STIM1 upon Ca2+ store depletion reaching a minimum after 30s of stimulation 
and then reinteracts with STIM1, and opposite results were observed when we tested the interaction of SARAF 
with Orai1, revealing that 30s after the initiation of Ca2+ store depletion there is an increase in SARAF-Orai1 
co-immunoprecipitation followed by a decrease in the association between both proteins. Using STIM1-deficient 
NG115-401L cells we have found that dissociation of SARAF and Orai1 observed 30 s after treatment with TG 
occurs independently of STIM1. The dynamic interactions of SARAF with STIM1 or Orai1 were found to occur 
with the same time courses, which might suggest that SARAF dissociates from STIM1 in the initial stages of Ca2+ 
store depletion to interact with Orai1, although the mechanism underlying this translocation is unclear at this 
stage.
The interaction of SARAF with Orai1 might transiently cooperate with STIM1 in the activation of Orai1 cur-
rents. However, the predominant role of SARAF on SOCE is the negative regulation of Ca2+ entry via activation 
of SCDI as evidenced by us in manoeuvres modifying the expression of SARAF in MEG01 cells endogenously 
expressing STIM1 and Orai1 or by other authors in different cell types17,18,31, where SARAF overexpression or 
silencing SARAF expression leads to attenuated or enhanced SOCE, respectively. The lack of observation of a 
positive role of SARAF on the initial stages of SOCE suggests that the transient stimulatory role of SARAF on the 
activation of Orai1 might be a redundant function in the presence of functional STIM1, which might mask this 
effect and evidence solely the long lasting negative regulatory role of SARAF underlying the activation of SCDI. 
Alternatively, the lack of detection of a transient positive effect of SARAF overexpression in the initial stages 
of SOCE might be attributed to a negative regulation of other STIM1-regulated channels involved in SOCE by 
SARAF, such as TRPC proteins23,32–34. Still remains to be resolved what is the functional role of SARAF in cells 
with a low expression of STIM1 but with a significant expression of Orai1 and other Ca2+ permeable channels. 
Our results indicate that, in cells with a low expression of STIM1, SARAF enhances Orai1 function, which might 
play a positive role in Ca2+ entry through store-independent mechanisms. Unveiling the role of SARAF on TRP 
channel function in cells with a low STIM1 expression might provide relevant information concerning the role of 
SARAF on store-independent Ca2+ entry.
In summary, on the base of the previous studies17,18 and our findings, we propose a model where SARAF 
modulates Orai1 channel function through direct and indirect interaction. At rest, SARAF is associated with the 
SOAR/OASF region of STIM1 via the CTID domain; however, upon Ca2+ store depletion SARAF transiently 
dissociates from STIM1 and associates with the C-terminal region of Orai1. A few seconds later, and probably 
mediated by the increase in [Ca2+]c, SARAF dissociates from Orai1 and reinteracts with STIM1. Dissociation of 
SARAF from Orai1, together with the subsequent association with STIM1 might have a role in the SCDI of Orai1.
Methods
Materials. Fura-2 acetoxymethyl ester (fura-2/AM), was from Molecular Probes (Leiden, The Netherlands). 
Thapsigargin (TG), ATP, rabbit polyclonal anti-Orai1 antibody (catalog number O8264, epitope: amino acids 
288–301 of human Orai1), Duolink® In Situ Red Starter Kit Mouse/Rabbit, mouse monoclonal anti-Orai1 anti-
body (clone ORAI1-89, epitope: synthetic peptide located near the C-terminus of human Orai1, catalog number: 
SAB4200273), rabbit polyclonal anti-β -actin antibody (catalog number A2066, epitope: amino acids 365–375 of 
human β -actin), and bovine serum albumin (BSA) were from Sigma (Madrid, Spain). Rabbit polyclonal anti-
TMEM66 (SARAF) antibody (catalog number PA5-24237. epitope: amino acids 33–62 of the N-terminal region 
of human TMEM66) and Turbofect transfection reagent were from Thermo Fisher (Madrid, Spain). Mouse mon-
oclonal anti STIM1 antibody (Clone 44/GOK, epitope: amino acids 25–139 of human STIM1, catalog num-
ber 610954) was from BD Transduction Laboratories (Frankin Lakes, NJ, U.S.A.). Calmidazolium chloride was 
from Bio-Rad (Madrid, Spain). Rabbit polyclonal anti-Orai1 antibody (catalog number: ab177021, epitope: 
peptide from the extracellular loop 2 region), horseradish peroxidase-conjugated anti-mouse IgG antibody and 
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anti-rabbit IgG antibody for IP (not recognizing the heavy and light chains of the immunoprecipitating antibody) 
were from Abcam (Madrid, Spain). Rabbit polyclonal anti-Orai1 antibody (catalog number: 4041, epitope: raised 
against an 18 amino acid synthetic peptide from near the N-terminus of human Orai1) was from Prosci (Fort 
Collins, CO, USA). Amaxa nucleofector kit C was purchased from (Lonza, Madrid, Spain). Protein A-agarose was 
from Upstate Biotechnology Inc. (Madrid, Spain). Mouse anti-GFP antibody (mixture of two monoclonal anti-
bodies, clones 7.1 and 13.1, which recognize both wild-type and mutant forms of GFP, such as YFP35; catalogue 
number 11814460001) and complete EDTA-free protease inhibitor tablets were from Roche (Madrid, Spain). 
Enhanced chemiluminescence detection reagents were from Pierce (Cheshire, U. K.). TransPass P was from New 
England Biolabs (Ipswich, MA, U.S.A.). Taq Polimerase, T4 ligase, EcoRI and EcoRV enzymes were from Takara 
(Bio Inc, Japan). Ultraclean GelSpin Kit® and Ultraclean Midi plasmid prep Kit® were from MoBio (MO BIO 
Laboratories, Carlsbad, USA). All other reagents were of analytical grade.
Plasmids construction. Plasmids were based on the previously published SARAF sequences 
(GenBank: JQ348891.1). The DNA of the complete cds was isolated from NG115-401L cells using spe-
cific primers (Forward: 5′  AAAAAACCCGGGATGGCCGCAGCCTGCGGGCC 3′; and reverse: 5′- 
AAAAAAGAATTCTTATCGTCTCCTGGTACCACCATAT-3′ ). Final cDNA was purified and cloned into the 
EcoRV site previously inserted in the pIRES2-eGFP-RV expression vector. Nucleotide sequence of this construct 
was verified by sequencing.
To knockdown expression of SARAF1, a pLKO.1-puro plasmid–based shRNA targeting the sequence: 
CGGACTTAGATATTGCATACA (clone ID: TRCN0000146643; Sigma-Aldrich) was used (SARAF-shRNA). 
In addition, a non-targeting shRNA plasmid (NT-shRNA) that targets no known human sequence was used 
as a control. A primer containing the target sequence along with a stem loop followed by the reverse tar-
get sequence was annealed to a complimentary primer and inserted into the EcoRI and AgeI sites of the 
pLKO.1-puro plasmid (Addgene; number 10878). The resulting hairpin consisted of the following sequence: 
5′ -CCGGCGGACTTAGATATTGCATACACTCGAGTGTATGCAATATCTAAGTCCGTTTTTTG-3′ . The 
correct insertion of the hairpin into pLKO.1 plasmid was finally checked by sequencing.
Cell culture and transfection. The megakaryoblastic cell line MEG01 was used in this study as a cellu-
lar model endogenously expressing STIM1. Moreover, STIM1-deficient NG115-401L cells were used for certain 
experimental procedures to avoid interference with endogenous STIM1. MEG01 and NG115-401L cell lines were 
obtained from ATCC (Manassas, VA, USA) and Sigma (Madrid, Spain), respectively, and cultured at 37 °C with 
a 5% CO2 in RPMI or DMEM, respectively, supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine 
and 100 U/mL penicillin and streptomycin.
Cells were transfected with expression plasmids for pIRES2-EGFP-SARAF, pEYFP-Orai1, pEYPF-OASF, the 
pEYFP-Orai1 N-terminal deletion mutants (Orai1 ΔN1–38, ΔN1–72 and ΔN1–89) or the pEYFP-Orai1 C-terminal 
deletion mutant (Orai1-ΔCtermin, amino acids 1–260) kindly provided by Dr. Romanin, as well as with the 
siSARAF or scramble plasmid as described previously36–38 using Amaxa nucleofector technology (for MEG-01 
cells) or Turbofect transfection reagent (for NG115-401L cells) and were used 48 h after transfection. For trans-
fection with antibodies we used transpass P following the manufacturer’s instructions and were used 6h after 
transfection.
Cell transfection with shOrai1 was performed as described previously39. For the shOrai1, the sense sequence 
was 5′ -CACCTCACTGGTTAGCCATAAGACGAATCTTATGGCTAACCAGTGA-3′ , and the antisense 
sequence was 5′ -AAAACCTTTACACGCTAGATGGTTTGCTCTTATGGCTAACCAGTGA-3′ . Plasmids were 
used for silencing experiments at 1 μg/μl.
Measurement of cytosolic free-calcium concentration ([Ca2+]c). Cells were loaded with fura-2 by 
incubation with 2 μM fura 2/AM for 30 min at room temperature. Coverslips with cultured cells were mounted 
on a perfusion chamber and placed on the stage of an epifluorescence inverted microscope (Nikon Diaphot T200, 
Melville, NY, USA) with image acquisition and analysis system for videomicroscopy (Hamamatsu Photonics, 
Hamamatsu, Japan). Cells were continuously superfused with HEPES-buffered saline (HBS) containing (in mM): 
125 NaCl, 5 KCl, 1 MgCl2, 5 glucose, 25 HEPES, and pH 7.3, supplemented with 0.1% (w/v) BSA.. Cells were 
alternatively excited with light from a xenon lamp passed through a high-speed monochromator (Polychrome 
IV, Photonics, Hamamatsu, Japan) at 340/380 nm. Fluorescence emission at 505 nm was detected using a cooled 
digital CCD camera (Hisca CCD C-6790, Hamamatsu, Japan) and recorded using Aquacosmos 2.5 software 
(Hamamatsu Photonics, Hamamatsu, Japan). Fluorescence ratio (F340/F380) was calculated pixel by pixel and data 
are presented as ΔF340/F380. ATP-evoked Ca2+ influx was measured as the integral of the rise in [Ca2+]c above basal 
for 1½ min after the addition of ATP in the presence of external Ca2+, corrected by subtraction of the integral over 
the same period for stimulation in the absence of external Ca2+ (with 100 μM EGTA).
Immunoprecipitation and Western blotting. The immunoprecipitation and Western blotting were per-
formed as described previously40. Briefly, 500 μL aliquots of cell suspension (4 × 106 cell/mL) were lysed with an 
equal volume of ice-cold 2× NP-40 buffer, pH 8, containing 274 mM NaCl, 40 mM Tris, 4 mM EDTA, 20% glyc-
erol, 2% nonidet P-40, 2 mM Na3VO4 and complete EDTA-free protease inhibitor tablets. Aliquots of cell lysates 
(1 mL) were immunoprecipitated by incubation with 1 μg of anti-STIM1 or 2 μg of anti-SARAF or anti-Orai1 
antibody and 25 μL of protein A-agarose overnight at 4 °C on a rocking platform. The immunoprecipitates were 
resolved by 8% SDS-PAGE and separated proteins were electrophoretically transferred onto nitrocellulose mem-
branes for subsequent probing. Blots were incubated overnight with 10% (w/v) BSA in tris-buffered saline with 
0.1% Tween 20 (TBST) to block residual protein binding sites. Immunodetection of Orai1, STIM1 and SARAF 
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was achieved by incubation for 2h with anti-STIM1 antibody diluted 1:250 in TBST, anti-Orai1 antibody diluted 
1:200 in TBST, the anti-SARAF antibody diluted 1:1000 in TBST and anti-calmodulin antibody diluted 1:500. 
The primary antibody was removed and blots were washed six times for 5 min each with TBST. To detect the 
primary antibody, blots were incubated for 1 h with horseradish peroxidase-conjugated goat anti-mouse IgG 
antibody or horseradish peroxidase-conjugated goat anti-rabbit IgG antibody diluted 1:10000 in TBST and then 
exposed to enhanced chemiluminiscence reagents for 4 min. The density of bands was measured using C-DiGit 
Chemiluminescent Western Blot Scanner. Data were normalized to the amount of protein recovered by the anti-
body used for the immunoprecipitation.
Proximity ligation assay. The PLA was performed using the Duolink® In Situ Red Starter Kit Mouse/
Rabbit and performed following the manufacturer’s instructions and as previously described41. After stimulation, 
the cells were fixed in ice-cold 4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min. The cells 
were then washed three times with PBS with agitation and permeabilized in PBS that contained 0.5% Triton 
X-100 for 10 min at room temperature, followed by washing the cells twice with 0.05% Tween 20 in Tris-buffered 
saline buffer (TBS, containing in mM: 50 Tris-HCl [pH 7.5] and 150 NaCl). Cells were then blocked for 30 min 
with one drop of Duolink Blocking solution in a humidified chamber at 37 °C and incubated for 1 h at 37 °C 
with appropriate combinations of antibodies diluted 1:100 in Duolink Antibody Diluent solution (40 μL). The 
antibodies used for the PLA were rabbit anti-TMEM66 (SARAF) (Thermo Fisher, Madrid, Spain) combined 
with mouse anti-Orai1 (Sigma, Madrid, Spain) or mouse anti-STIM1 (BD Transduction Laboratories, Frankin 
Lakes, NJ, U.S.A.). After washing with Wash Buffer A, the cells were incubated for 1 h at 37 °C with PLA probes, 
which are secondary antibodies (Duolink® In Situ PLA Probe anti-rabbit PLUS or Duolink® In Situ PLA Probe 
anti-mouse MINUS) conjugated to unique oligonucleotides. The cultures were further subjected to in situ PLA 
using a Duolink Detection kit according to the manufacturer’s instructions. Briefly, the slides were incubated 
with Ligation-Ligase solution in a pre-heated humidified chamber for 30 min at 37 °C, followed by incubation 
with amplification polymerase solution for an additional 100 min at 37 °C. Finally, the cells were washed in Wash 
Buffer B, and the slides were mounted using Mounting Medium with DAPI® and evaluated using a Eclipse TE300 
fluorescence microscope with a × 60 oil-immersion objective (Nikon Corporation, Tokyo, Japan). The quantifi-
cation of PLA signals was performed using ImageJ software (NIH, U.S.A.). The processed images were thresh-
olded and the in situ PLA signals per cell were quantified. The settings were kept constant for all of the images 
throughout the experiments. Quantifications were performed from 30 to 40 images from a minimum of four 
slides for each treatment corresponding to 100–200 cells. Mouse anti-Orai1 directed towards the C-terminus (cat-
alog number SAB4200273, Sigma) combined with rabbit anti-Orai1 directed towards 18 amino acids located in 
the N-terminal region of human Orai1 (catalog number 4041, Prosci) was used as a positive control. As a negative 
technical control, the primary antibodies were used alone, or both primary antibodies were omitted. The negative 
controls did not yield any significant PLA signals at any treatment condition.
Statistical Analysis. Analysis of statistical significance was performed using one-way analysis of variance. 
For comparison between two groups Student’s t test was used. P < 0.05 was considered to be significant for a 
difference.
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